Tetraphase Pharmaceuticals (NASDAQ:TTPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Several other research analysts also recently weighed in on TTPH. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. BMO Capital Markets boosted their price objective on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. HC Wainwright boosted their price objective on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, November 6th. Finally, ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $15.15.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up $0.01 during trading on Friday, hitting $6.52. 412,100 shares of the stock traded hands, compared to its average volume of 480,525. The stock has a market capitalization of $334.20, a P/E ratio of -2.27 and a beta of 2.51. Tetraphase Pharmaceuticals has a 1-year low of $3.57 and a 1-year high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, hitting the consensus estimate of ($0.63). The business had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The firm’s quarterly revenue was up 355.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.58) earnings per share. equities research analysts forecast that Tetraphase Pharmaceuticals will post -2.88 EPS for the current year.
In other news, insider Jacques Dumas sold 7,167 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total value of $44,507.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director L Patrick Gage acquired 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction dated Wednesday, November 29th. The stock was purchased at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the purchase, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.
Institutional investors have recently modified their holdings of the company. California Public Employees Retirement System lifted its stake in shares of Tetraphase Pharmaceuticals by 2.0% in the second quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock worth $1,727,000 after buying an additional 4,800 shares during the last quarter. EcoR1 Capital LLC acquired a new stake in shares of Tetraphase Pharmaceuticals in the second quarter worth $4,516,000. Northern Trust Corp lifted its stake in shares of Tetraphase Pharmaceuticals by 4.8% in the second quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock worth $6,323,000 after buying an additional 40,668 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its stake in shares of Tetraphase Pharmaceuticals by 95.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 393,000 shares of the biopharmaceutical company’s stock worth $2,688,000 after buying an additional 192,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Tetraphase Pharmaceuticals by 73.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock worth $7,853,000 after buying an additional 466,955 shares during the last quarter. Institutional investors and hedge funds own 58.15% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2018/01/12/tetraphase-pharmaceuticals-ttph-upgraded-by-zacks-investment-research-to-hold.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.